Thrombocyte HLA molecules retain nonrenewable endogenous peptides of megakaryocyte lineage and do not stimulate direct allocytotoxicity in vitro

被引:41
作者
Gouttefangeas, C
Diehl, M
Keilholz, W
Hörnlein, RF
Stevanovic, S
Rammensee, HG
机构
[1] Inst Cell Biol, Dept Immunol, D-72076 Tubingen, Germany
[2] Univ Tubingen Hosp, Dept Transfus Med, Tubingen, Germany
关键词
D O I
10.1182/blood.V95.10.3168.010k11_3168_3175
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The origin and the function of HLA class I molecules present on the surface of human platelets are still unclear. In particular, it is controversial which fraction of these class I molecules represents integral membrane components derived from the megakaryocyte-platelet lineage versus soluble plasma HLA molecules acquired by adsorption. Results of the present study show that HLA-A2 ligands isolated from platelets possess the same peptide motif as described for HLA-A2-associated peptides obtained from nucleated cells. Sequencing of these platelet- derived peptides reveals that they originate mainly from ubiquitously expressed proteins also present in the megakaryocyte-platelet lineage. Moreover, one of these peptides derives from the GPIX protein, which is specifically expressed by platelets and their precursors. Platelet HLA molecules are unstable in vitro at 37 degrees C, but can be partially stabilized by addition of exogenous beta(2)-microglobulin and HLA class I binding peptide, suggesting that platelets cannot load HLA molecules with endogenous peptides. In in vitro experiments platelets were used to stimulate peripheral blood mononuclear cells, No allospecific cytotoxicity was observed after primary stimulation, or secondary restimulation, with allogenic resting or activated platelets, even in the presence of additional third-party helper activity. These data indicate that HLA class I molecules from platelets cannot directly induce allogenic CD8(+) cytotoxic T-cell response in vitro. (C) 2000 by The American Society of Hematology.
引用
收藏
页码:3168 / 3175
页数:8
相关论文
共 45 条
[31]  
PANCRE V, 1987, J IMMUNOL, V138, P4490
[32]  
PEREIRA J, 1988, BLOOD, V71, P516
[33]  
Rammensee HG, 1997, MHC LIGANDS PEPTIDE
[34]   THE PRESENCE OF MESSENGER-RNA FOR HLA CLASS-I IN HUMAN PLATELETS AND ITS CAPABILITY FOR PROTEIN-BIOSYNTHESIS [J].
SANTOSO, S ;
KALB, R ;
KIEFEL, V ;
MUELLERECKHARDT, C .
BRITISH JOURNAL OF HAEMATOLOGY, 1993, 84 (03) :451-456
[35]   HLA ANTIGENS ON PLATELET MEMBRANES - INVITRO AND INVIVO STUDIES [J].
SANTOSO, S ;
MUELLERECKHARDT, G ;
SANTOSO, S ;
KIEFEL, V ;
MUELLERECKHARDT, C .
VOX SANGUINIS, 1986, 51 (04) :327-333
[36]   Frequency and specificity of platelet-specific alloantibodies in HLA-immunized haematologic-oncologic patients [J].
Schnaidt, M ;
Northoff, H ;
Wernet, D .
TRANSFUSION MEDICINE, 1996, 6 (02) :111-114
[37]   The HLA-B*1516 moth demonstrates HLA-B-specific P2 pocket characteristics [J].
Seeger, FH ;
Arnold, D ;
Dumrese, T ;
de la Salle, H ;
Fricker, D ;
Schild, H ;
Rammensee, HG ;
Stevanovic, S .
IMMUNOGENETICS, 1998, 48 (02) :156-160
[38]   Extreme leukoreduction of major histocompatibility complex class II positive B cells enhances allogeneic platelet immunity [J].
Semple, JW ;
Speck, ER ;
Cosgrave, D ;
Lazarus, AH ;
Blanchette, VS ;
Freedman, J .
BLOOD, 1999, 93 (02) :713-720
[39]   INDIRECT ALLORECOGNITION OF PLATELETS BY T-HELPER CELLS DURING PLATELET TRANSFUSIONS CORRELATES WITH ANTI-MAJOR HISTOCOMPATIBILITY COMPLEX ANTIBODY AND CYTOTOXIC T-LYMPHOCYTE FORMATION [J].
SEMPLE, JW ;
SPECK, ER ;
MILEV, YP ;
BLANCHETTE, V ;
FREEDMAN, J .
BLOOD, 1995, 86 (02) :805-812
[40]  
SUGAWARA S, 1987, J IMMUNOL METHODS, V100, P83